MT-act is a CNRS spin-off. #techtransfer We develop class compounds to treat human pathologies that share a common molecular defect; dysfunction of the skeleton of the cells called microtubules - abbreviated MT. Stiffening of the skeleton of our cells is a central disease driver. That is why we act on them. We developed a technology platform to charter an entirely neglected pharmaceutical space. MT-act prioritizes indications based on scientific evidence, proven unmet medical needs and where the roadmap to patients is feasible and desired.